Results 71 to 80 of about 1,603 (142)

Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide through glutathione-depletion in imatinib-resistant cells

Haematologica, 2007
The development of resistance to imatinib mesylate may partly depend on high Bcr-Abl-expression levels. Arsenic trioxide (ATO) has Bcr-Abl suppressing activity in vitro.
Heiko Konig, Nicolai Härtel, Beate Schultheis, Michael Schatz, Christian Lorentz, Junia V. Melo, Rüdiger Hehlmann, Andreas Hochhaus, Paul La Rosée   +8 more
doaj   +1 more source

Oxidative Stress in the Tumor Immune Microenvironment: Mechanisms and Therapeutic Perspectives

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Oxidative stress is involved in several key processes in cancer, including redox regulation, DNA damage, post‐translational modifications, transcriptional regulation, epigenetic modifications, metabolic reprogramming, cell death, and immune modulation. These mechanisms collectively influence tumor progression, immune evasion, and therapeutic responses,
Zhen Wang, Bowen Li, Pan Tang, Fanchen Yan, Shuxin Wang, Guiying Leng, Panduo Dawa, Yuansi Chen, Yihan Guo, Pan Yang, Yi Li, Siyu Liu, Erdan Dong, Siyuan Qin, Zhoufeng Wang   +14 more
wiley   +1 more source

The Aging Microenvironment Shapes Angiogenic Remodeling in IBD‐Associated Colorectal Carcinogenesis

Aging Cell, Volume 25, Issue 6, June 2026.
In IBD, chronic inflammation promotes cellular senescence across epithelial, stromal, endothelial, and immune compartments. The resulting SASP drives pathological angiogenesis, vascular dysfunction, hypoxia, and immune suppression, thereby facilitating progression from inflammation to dysplasia and colitis‐associated colorectal cancer.
Ruoshu Duan, Qingyu Chen, Yuan Xu, Ye Yan, Sujing Jiang   +4 more
wiley   +1 more source

Targeted disruption of the BCR-ABL fusion gene by Cas9/dual-sgRNA inhibits proliferation and induces apoptosis in chronic myeloid leukemia cells

Acta Biochimica et Biophysica Sinica
The BCR-ABL fusion gene, formed by the fusion of the breakpoint cluster region protein (BCR) and the Abl Oncogene 1, Receptor Tyrosine Kinase (ABL) genes, encodes the BCR-ABL oncoprotein, which plays a crucial role in leukemogenesis.
Zeng Jianling, Liang Xinquan, Duan Lili, Tan Fenghua, Chen Liujie, Qu Jiayao, Li Jia, Li Kai, Luo Dixian, Hu Zheng   +9 more
doaj   +1 more source

A Comprehensive Echocardiographic Assessment of Patients With Chronic Myeloid Leukemia on Dasatinib

Echocardiography, Volume 43, Issue 6, June 2026.
In a retrospective cohort of 199 adult patients with CML on Dasatinib in a single quaternary center, approximately 25% patients had routine baseline and follow‐up echocardiogram. Dasatinib was associated with significant changes in structural and diastolic parameters.
Chen Chen, Vinesh Appadurai, Maria Paulina Hernandez, Jessica Altman, Nausheen Akhter   +4 more
wiley   +1 more source

Prophylactic Donor Lymphocyte Infusions in Pediatric Patients With High‐Risk Hematological Malignancies

European Journal of Haematology, Volume 116, Issue 6, Page 907-914, June 2026.
ABSTRACT Introduction Allogeneic stem cell transplantation (allo‐SCT) and donor lymphocyte infusions (DLI) can elicit a graft‐versus‐leukemia (GvL) effect in pediatric patients with hematological malignancies. We report our single‐center experience with prophylactic DLI in high‐risk pediatric patients with leukemia or lymphoma, focusing on feasibility,
Denise Epple, Katja Gall, Luisa Paschke, Hans‐Jochem Kolb, Angela Wawer, Hans Knabe, Irene von Luettichau, Julia Hauer, Uwe Thiel   +8 more
wiley   +1 more source

Cardiac arrhythmias of BCR-ABL inhibitors with or without triazole antifungal agents: A real-world pharmacovigilance study based on the food and drug administration adverse event reporting system database

SAGE Open Medicine
Objectives: Breakpoint Cluster Region (BCR)-Abelson tyrosine kinase (ABL) inhibitors are widely used in the treatment of blood cancers, particularly chronic myelogenous leukemia and are often combined with triazole antifungal agents to prevent fungal ...
Peitao Xie, Lishan Lu, Yixuan Tian, Rongrong Jia, Xuemei Tian, Pu Bai   +5 more
doaj   +1 more source

Targeting USP10–FAK pathway sensitizes BCR-ABL+ leukemia cells to tyrosine kinase inhibitors

Cell Investigation
BCR-ABL+ leukemia is driven by constitutive tyrosine kinase activity, and tyrosine kinase inhibitors (TKIs) are the standard therapy. However, resistance to TKIs remains a significant clinical challenge.
Kangjie Qiu, Xianfeng Wang, Zhen Liu, Xueting Peng, Shuxin Zhong, Zhangshuai Dai, Xianfeng Zha, Peipei Wang, Chengwu Zeng   +8 more
doaj   +1 more source

The NF‐κB Signalling Pathway: Mechanisms, Consequences and Therapeutic Targets

Journal of Cellular and Molecular Medicine, Volume 30, Issue 11, June 2026.
ABSTRACT Nuclear Factor‐kappa B (NF‐κB) is a master transcriptional regulator orchestrating critical cellular processes, predominantly immunity and inflammation. However, its aberrant constitutive activation has emerged as a unifying pathogenetic hallmark across diverse malignancies, autoimmune disorders, and chronic inflammatory diseases.
Bherouz Pourdad, Arash Pourdad
wiley   +1 more source

Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)

Molecular Cancer, 2012
Background Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemias (Ph-positive ALL) with clinically approved inhibitors of the Bcr/Abl tyrosine kinase frequently results in the emergence of a leukemic clone carrying the T315I ...
Fei Fei, Lim Min, Schmidhuber Sabine, Moll Jürgen, Groffen John, Heisterkamp Nora   +5 more
doaj   +1 more source